Pathologic gambling in Parkinson's disease: A behavioral manifestation of pharmacologic treatment?

Molina, José Antonio; Sáinz‐Artiga, María José; Fraile, Alicia; Jiménez‐Jiménez, Félix Javier; Villanueva, Clara; Ortı́-Pareja, M; Bermejo‐P, Félix

doi:10.1002/1531-8257(200009)15:5<869::aid-mds1016>3.0.co;2-i

Cited by 243 publications

(142 citation statements)

References 17 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…85 (Large-scale, prospective, controlled trials have yet to be reported.) Although the first report in 2000 implicated LD in 12 cases of fluctuating PD, 86 the case series that followed implicated DA agonists and, more specifically, pramipexole. 87,88 The lifetime prevalence of PG was greater for those prescribed DA agonists (7.2%) than for PD populations with all treatment combinations (3.4%).…”

Section: Safety Issues: Pathological Gambling and Related Impulse Conmentioning

confidence: 99%

“…There are also data supporting an association with LD therapy, amantadine, and (although this is not universally supported) deep brain stimulation surgery. 86,89,91,92,95 Furthermore, there are increasing data to suggest that PG may be disease-related, with reports of onset without change in medications, lack of relation to agonist dosages, continuing symptoms after stopping DA agonists in a notable portion of cases, spontaneous reversal without medication changes, and particular disease-related risk factors (including young age of onset, longer disease duration, association with prior history of alcoholism and other ICD, mania, executive dysfunction, and novelty seeking). 80,81,86,90,94,96 There are also significant psychiatric and motor comorbidities; depression, disinhibition, irritability, appetite changes and mania or hypomania.…”

Section: Safety Issues: Pathological Gambling and Related Impulse Conmentioning

confidence: 99%

See 1 more Smart Citation

Current Status of Symptomatic Medical Therapy in Parkinson’s Disease

Factor

2008

Neurotherapeutics

View full text Add to dashboard Cite

Summary: Symptomatic medical therapies for Parkinson's disease (PD) have been disease modifying and have led to improvement in daily function, quality of life, and survival. For 40 years, these therapies have been primarily dopaminergic, and currently include the dopamine (DA) precursor levodopa (LD), DA agonists, catechol-O-methyltransferase (COMT) inhibitors, and monoamine oxidase (MAO) inhibitors. The roles of all these classes of agents have evolved, with significant changes occurring since the early 2000s. This article reviews the current literature for each of these classes of drugs, with a focus on efficacy and place in the therapeutic scheme. Levodopa is no longer considered to be toxic and, thus, its early use is not only appropriate but recommended.Ergot agonists are no longer in use, and new agents administered in patch form or subcutaneous injections have been approved. The COMT inhibitor tolcapone, with its significant efficacy, has been reintroduced, and two new MAO inhibitors have been approved. Selected safety issues are discussed, including the incidence of melanoma in relation to LD; pathological gambling and DA agonists; hepatic toxicity of tolcapone; and the tyramine or so-called cheese reaction with MAO B inhibitors. The article closes with a discussion of future directions and new drugs under development.

show abstract

Section: Safety Issues: Pathological Gambling and Related Impulse Conmentioning

confidence: 99%

Section: Safety Issues: Pathological Gambling and Related Impulse Conmentioning

confidence: 99%

Current Status of Symptomatic Medical Therapy in Parkinson’s Disease

Factor

2008

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…The real prevalence of ICD in PD patients on dopamine agonists (DA) treatment is unknown, but it has been suggested that it could range from 2% to 13.7% 2,3,4,5,6 . Since Molina et al 7 reported the association between the pharmacologic treatment of PD and PG for the first time in 2000, several reports have since implicated different dopaminergic drugs with ICDs, especially DA 7,8,9 . However piribedil, a non-ergot derived DA had not been associated with ICD until 2010 when Tschopp et al reported 4 PD patients on piribedil who developed PG 10 .…”

mentioning

confidence: 99%

Piribedil and Pathological Gambling in six Parkinsonian patients

Micheli

Giugni

Espinosa

et al. 2015

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Impulse control disorders (ICD) in Parkinson's disease (PD) have attracted increasing interest. They are characterized by the inability to control the impulse to perform an act that can be detrimental to them or to others. Although dopamine agonists (DA), as a group, have been associated with impulse control disorders (ICD), piribedil has rarely been reported to cause them. Method Case reports of six parkinsonian patients on piribedil presenting pathological gambling (PG). Results All of the patients presented ICD associated with piribedil use. Two of them received this medication as first treatment and four of them who had developed ICDs secondary to other DA that reappeared with piribedil. Conclusion Despite piribedil is commercially available in only a few countries, it should be considered in the differential diagnosis of PG in patients with PD.

show abstract

“…the central dopaminergic reward system has been implicated, possibly due to overstimulation of mesolimbic dopamine receptors. 1 recognized icds in this setting include pathologic gambling, [2][3][4][5][6][7] hypersexuality, [7][8][9] compulsive shopping, 7,9 compulsive eating, 10 punding, [11][12][13][14] and compulsive medication use. 15 punding is characterized by complex, stereotyped, and often purposeless repetitive actions such as continued handling or sorting of common objects, manipulation of technical equipment, excessive grooming or cleaning, and hoarding.…”

mentioning

confidence: 99%

“…20 Numerous reports in the literature confirm a similar striking relationship between icds and the use of dopaminergic agents in pd. [1][2][3][4][5][6][7][8][9][10]12,15 A consistent dose effect has not been demonstrated. 1 the relationship between icds and the use of dopaminergic medications in disease processes other than pd has not been as well studied.…”

mentioning

confidence: 99%

Impulse Control Disorders with the use of Dopaminergic Agents in Restless Legs Syndrome: a Case-Control Study

Cornelius

Tippmann‐Peikert

Slocumb

et al. 2010

Sleep

View full text Add to dashboard Cite

study objectives: To determine the frequency of impulse control disorders (ICDs) with the use of dopaminergic agents in restless legs syndrome (RLS). design: Prospective case-control study using a screening questionnaire for ICDs, followed by phone interview to confirm diagnoses for those meeting preset scoring thresholds on the questionnaire. setting: Academic, comprehensive sleep medicine center. patients or participants: (1) One hundred patients with RLS treated with dopaminergic agents, (2) 275 patients with obstructive sleep apnea (OSA) without RLS or exposure to dopaminergic agents; and (3) 52 patients with RLS who were never treated with dopaminergic agents. Subjects with parkinsonism were excluded. interventions: Not applicable. measurements and results: Based on the questionnaire, frequencies of ICDs for the RLS treatment group were 10% compulsive shopping, 7% pathologic gambling, 23% compulsive eating, 8% hypersexuality, and 10% punding. These values were statistically significant when compared with control subjects with OSA for compulsive shopping and pathologic gambling. With additional information from the phone interview, adjusted frequencies for the RLS treatment group were 9% compulsive shopping, 5% pathologic gambling, 11% compulsive eating, 3% hypersexuality, 7% punding, and 17% any ICD. These values were statistically significant when compared with those of control subjects with OSA for compulsive shopping, pathologic gambling, punding, and any ICD, as well as for compulsive shopping when compared with control subjects with RLS who were not treated with dopaminergic agents. In the RLS treatment group, a statistically significant dose effect was found for pramipexole in those subjects confirmed to have ICDs by both the questionnaire and phone interview. Mean duration of treatment at ICD onset was 9.5 months. conclusions: ICDs are common with the use of dopaminergic agents for treatment of RLS. Given the potentially devastating psychosocial consequences of these behaviors, it is critical to actively screen for ICDs in this population. Keywords: Restless legs syndrome, dopamine, impulse control citation: Cornelius JR; Tippmann-Peikert M; Slocumb NL; Frerichs CF; Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. SLEEP 2010;33(1):81-87.

show abstract

Pathologic gambling in Parkinson's disease: A behavioral manifestation of pharmacologic treatment?

Cited by 243 publications

References 17 publications

Current Status of Symptomatic Medical Therapy in Parkinson’s Disease

Current Status of Symptomatic Medical Therapy in Parkinson’s Disease

Piribedil and Pathological Gambling in six Parkinsonian patients

Impulse Control Disorders with the use of Dopaminergic Agents in Restless Legs Syndrome: a Case-Control Study

Contact Info

Product

Resources

About